SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB ), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that the company will present data from its ANB020 program, its wholly-owned anti-IL-33 antibody, at the 2017 American Academy of Dermatology (AAD) Annual Meeting and the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting. The AAD Annual Meeting is being held March 3-7, 2017 at the Orange County Convention Center in Orlando, Fla., and the AAAAI Annual Meeting is being held March 3-6, 2017 at the Georgia World Congress Center in Atlanta.
Details of the presentations are as follows:
AAD Annual Meeting Oral Presentation Date: Friday, March 3, 2017 Time: 2:55 – 3:00 p.m. ET Abstract Title: 5039. A Phase 1 Study of ANB020, an Anti-IL-33 Monoclonal Antibody, in Healthy Volunteers Location: e-Poster Presentation Center 3
AAAAI Annual Meeting Poster Presentation Date: Saturday, March 4, 2017 Time: 9:45 -10:45 a.m. ET Abstract Title: 30949. A Phase 1 Study of ANB020, an Anti-IL-33 Monoclonal Antibody, in Healthy Volunteers Poster Number: 232 Session Number: 2213 Session Title: Innate Lymphoid Cells, T-Cells and Dendritic Cells Location: Georgia World Congress Center, Level One, South Exhibit Hall B2
About ANB020 ANB020 is a potentially first-in-class antibody that inhibits the activity of IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 directly mediates the release of disease-associated cytokines, which recruit pro-inflammatory cells that mediate atopic disease. Because ANB020 inhibits IL-33 function and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has recently been genetically validated through human studies published in the medical literature. We have cleared a U.S. IND and a U.K. CTA to initiate Phase 2a trials of ANB020 for the treatment of severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, where we anticipate top-line data from these trials to be announced during the second half of 2017. In addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma, where we anticipate top-line data from this trial to be announced during the first half of 2018.
About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio's antibody pipeline has been developed using its proprietary SHM platform, which uses in vitro somatic hypermutation for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in partnership with Celgene and TESARO, including an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are currently under clinical development with TESARO, and an undisclosed anti-inflammatory antibody currently in the clinic with Celgene.
Contact: Monique Allaire THRUST Investor Relations 617.895.9511 monique@thrustir.com
